Pharmacological Approaches to the Treatment of Intermittent Claudication

Drugs & Aging

Volumn 2, Issue 2, 1992, Pages 125-136

  Bevan, E G ^a   Waller, P C ^b   Raay, L E ^c  

^a WESTERN INFIRMARY   (United Kingdom)

^b MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; VASODILATOR AGENT;

AGED; CLINICAL TRIAL; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; MALE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

AGED; ANTICOAGULANTS; FEMALE; HUMAN; INTERMITTENT CLAUDICATION; MALE; RANDOMIZED CONTROLLED TRIALS; VASODILATOR AGENTS;

EID: 0026827946     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/00002512-199202020-00006     Document Type: Review

References (76)

1. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications
2. Naftidrofuryl in chronic arterial disease: results of a six month controlled multicenter study using Naftidrofuryl tablets 200mg
3. Changes of walking distance in patients with intermittent claudication during six months intensive physical training
4. Secondary prevention of vascular disease by prolonged antiplatelet treatment
5. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial
6. Intermittent claudication: an update on management
7. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs?
8. Double-blind study of pentoxifylline against cardiovascular events in subjects suffering from intermittent claudication
9. Can drugs help patients with lower limb ischaemia?
10. Placebo-controlled, double-blind, two-centre trial of ketanserin in intermittent claudication
11. Vasodilating drugs in peripheral vascular disease
12. Placebo-controlled trial of ketanserin in the treatment of intermittent claudication
13. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinic trials, 1965–1985
14. Angioplasty for intermittent claudication
15. Pentoxifylline (Trental): a new drug for the treatment of peripheral chronic occlusive arterial disease
16. Effect of ketanserin in the treatment of patients with intermittent claudication: results from 13 placebo-controlled parallel group studies
17. A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication
18. Intermittent claudication: not so benign
19. New drug therapy in peripheral vascular disease
20. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from non-invasive testing in a defined population
21. Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication
22. Placebo-controlled double-blind study with pentoxifylline of walking performance in patients with intermittent claudication
23. Does oxpentifylline have a place in the treatment of intermittent claudication?
24. Clinic, haemodynamic, Theological and biochemical findings in 126 patients with intermittent claudication
25. Prostaglandin E1 and human platelets
26. Effect of prostaglandin E1 on platelet behaviour in vitro and in vivo
27. Placebo-controlled double-blind study of haemodilution in peripheral arterial disease
28. Intermittent claudication
29. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans
30. Limb salvage in elderly patients. Is aggressive surgical therapy warranted?
31. Intermittent claudication: a double-blind crossover trial of pentoxifylline
32. The case against vasodilator drugs in occlusive vascular disease of the legs
33. The effect of pentoxifylline on red cell flexibility in healthy subjects after administration of Trental 400
34. Epidemiology of intermittent claudication: evaluation of risk factors
35. Lack of effect of a 24-hour infusion of iloprost in intermittent claudication
36. Treating claudication in five words
37. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study
38. Metabolic fuels during and after severe exercise in athletes and nonathletes
39. Cessation of smoking in patients with intermittent claudication: effects on the risk of peripheral vascular complications, myocardial infarction and mortality
40. Effects of physical training on different categories of patients with intermittent claudication
41. Update on some epidemiologic features of intermittent claudication: the Framingham Study
42. Effects of naftidrofuryl in patients with intermittent claudication
43. Hemodynamic effects of Iloprost, a prostacyclin analogue
44. Useless drugs are not placebos: lessons from flunarizine and cinnarizine
45. Effect of daily muscular exercise in patients with intermittent claudication
46. Treatment of claudication with dipyridamole and aspirin
47. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group
48. Ticlopidine: an updated review of its pharmacology and therapeutic use in platelet-dependent disorders
49. Effet du naftidrofuryl sur le metabolisme energetique cerebral
50. Prostaglandins in vascular disease: a seminal approach
51. Clinical effects of intravenous Iloprost in patients with intermittent claudication
52. Aspirin all round?
53. Randomized placebo-controlled double-blind trial of ketanserin in claudicants: changes in claudication distance and ankle systolic pressure
54. Prevention of atherosclerotic complications: controlled trial of ketanserin
55. Pentoxifylline efficacy in the treatment of intermittent claudication: multicentre controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients
56. The measured effect of stopping smoking on intermittent claudication
57. Placebo-controlled comparison of captopril, atenolol, labetalol and pindolol in hypertension complicated by intermittent claudication
58. Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration
59. Naftidrofuryl for intermittent claudication: a double-blind controlled trial
60. The effect of pentoxifylline on erythrocyte deformability and on phosphastide fatty acid distribution in the erythrocyte membrane
61. The effect of naftidrofuryl on the metabolic response to exercise in man
62. Pseudoclaudication: a review of etiology, diagnosis and treatment
63. Changes in blood viscosity induced by pentoxifylline
64. Beta-blockade and intermittent claudication: placebo-controlled comparison of atenolol and nifedipine and their combination
65. Cerebroactive drugs: clinical pharmacology and therapeutic role in cerebrovascular disorders
66. Double-blind crossover study of the clinical efficacy and haemorrheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs
67. Naftidrofuryl in chronic arterial disease: results of a controlled multicenter study
68. Current therapy for intermittent claudication
69. The acute effects of cigarette smoking on treadmill exercise distances in patients with stable intermittent claudication
70. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy
71. The effect of naftidrofuryl (Praxilene) on intermittent claudication
72. Occlusion of peripheral arteries: a study of 6,400 working subjects